Order Article Reprints

Gu X, Li X, Li H, Liu N, Xu Y, Li K, Zhang J, Wang X, Zhang X, Ding Y, et al. Preclinical Safety Profile of Deg-AZM, a Clinical-Stage New Transgelin Agonist: hERG Inhibition Study In Vitro, Cardiovascular–Respiratory Pharmacology, and Single/Repeated-Dose Toxicity in Beagle Dogs. Biomedicines. 2025; 13(9):2180. https://doi.org/10.3390/biomedicines13092180

Gu, Xiaoting, Xiaohe Li, Hailong Li, Nannan Liu, Ying Xu, Keran Li, Jia Zhang, Xiaoting Wang, Xiaoting Zhang, Yanjie Ding, and et al. 2025. "Preclinical Safety Profile of Deg-AZM, a Clinical-Stage New Transgelin Agonist: hERG Inhibition Study In Vitro, Cardiovascular–Respiratory Pharmacology, and Single/Repeated-Dose Toxicity in Beagle Dogs" Biomedicines 13, no. 9: 2180. https://doi.org/10.3390/biomedicines13092180

Gu, X., Li, X., Li, H., Liu, N., Xu, Y., Li, K., Zhang, J., Wang, X., Zhang, X., Ding, Y., Zhou, H., Ai, X., & Yang, C. (2025). Preclinical Safety Profile of Deg-AZM, a Clinical-Stage New Transgelin Agonist: hERG Inhibition Study In Vitro, Cardiovascular–Respiratory Pharmacology, and Single/Repeated-Dose Toxicity in Beagle Dogs. Biomedicines, 13(9), 2180. https://doi.org/10.3390/biomedicines13092180